Salivary duct carcinoma — one of the most aggressive and clinically distinctive of all salivary gland malignancies, representing approximately 6–10% of salivary gland carcinomas, predominantly affecting older male patients (male-to-female ratio approximately 3–4:1, with a peak incidence in the sixth and seventh decades), arising most frequently in the parotid gland (approximately 70–80% of cases) and less commonly the submandibular gland, with rare minor salivary gland origin, presenting most often as a rapidly enlarging, painful parotid mass with frequent facial nerve involvement, lymph node metastasis (present in approximately 50–60% of patients at presentation), and high rates of distant metastasis (lung, liver, bone — present in approximately 20–30% at diagnosis), characterized pathologically by histologic resemblance to high-grade invasive ductal carcinoma of the breast — with large ductal structures showing central comedonecrosis, Roman bridge formations, cribriform glands, and solid nests of pleomorphic cells with abundant eosinophilic cytoplasm, vesicular nuclei, prominent nucleoli, high mitotic activity, and frequent lymphovascular and perineural invasion — and defined by a molecular and immunohistochemical profile that makes it among the most therapeutically targetable of all salivary gland carcinomas: androgen receptor (AR) expression in approximately 70–90% of cases (the highest AR positivity rate of all salivary gland carcinomas), HER2 overexpression (IHC 3+ or FISH-amplified) in approximately 25–40% of cases (the highest HER2 positivity rate among salivary gland carcinomas), and recurrent somatic mutations in HRAS (approximately 15–20%), PIK3CA, TP53 (approximately 50%), PTEN, and NF1, with the combination of AR and HER2 expression creating a molecular phenotype analogous to the ER-positive/HER2-positive breast cancer subtype and providing multiple therapeutic targets, with treatment for localized disease being total parotidectomy (facial nerve sacrifice frequently required due to perineural invasion and direct nerve involvement) with ipsilateral neck dissection (standard given the high rate of nodal metastasis) followed by adjuvant radiotherapy (IMRT to the primary site and regional nodes — standard for virtually all resected salivary duct carcinomas given the high-grade behavior, perineural invasion, and nodal positivity), and with systemic therapy for recurrent or metastatic salivary duct carcinoma including trastuzumab and pertuzumab (for HER2-positive disease — the salivary gland carcinoma subtype with the strongest evidence for HER2-directed therapy, based on the NCCN and international guidelines recommending trastuzumab-based regimens for HER2-amplified salivary duct carcinoma); androgen deprivation therapy with leuprolide plus bicalutamide or enzalutamide (for AR-positive disease — with response rates of approximately 20–30% in first-line androgen deprivation trials for AR+ salivary duct carcinoma); trastuzumab deruxtecan (T-DXd, an antibody-drug conjugate) for HER2-overexpressing disease after trastuzumab progression; and combination AR plus HER2 targeting for dual-positive tumors — making integrated head and neck surgical oncology, radiation oncology, medical oncology (with breast oncology collaboration given shared HER2/AR targeting principles), surgical pathology, and molecular profiling platforms essential.
Salivary duct carcinoma technology platforms — whether supporting the surgical pathology programs performing salivary duct carcinoma diagnosis (high-grade ductal histology confirmation; AR IHC quantification — Allred score or H-score; HER2 IHC scoring using breast cancer criteria [IHC 0/1+/2+/3+] and FISH amplification for IHC 2+ equivocal cases; GATA3 IHC; gross cystic disease fluid protein-15 [GCDFP-15] IHC; androgen receptor pathway scoring; TP53 mutation NGS; HRAS mutation NGS; PIK3CA mutation NGS; comprehensive molecular profiling), the head and neck surgery programs performing total parotidectomy with facial nerve sacrifice (and immediate sural nerve cable graft reconstruction planning), ipsilateral neck dissection, and free flap reconstruction for large resections, the radiation oncology programs delivering adjuvant IMRT to the primary site and regional nodes, the medical oncology programs managing HER2-directed therapy (trastuzumab + pertuzumab, T-DXd), androgen deprivation therapy (leuprolide + bicalutamide, enzalutamide), and cytotoxic chemotherapy (carboplatin/paclitaxel, cisplatin), the molecular profiling platforms performing HER2 IHC and FISH, AR IHC, comprehensive NGS, and TMB/MSI determination, and the multidisciplinary head and neck tumor board programs integrating surgical, radiation, and systemic oncology expertise — must maintain the availability and performance standards that salivary duct carcinoma's aggressive biology, high nodal metastasis rate, HER2 and AR molecular profiling-driven systemic therapy, facial nerve sacrifice reconstruction, and rapid distant metastasis surveillance demand. This guide explains why salivary duct carcinoma tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the HER2/AR molecular profiling, total parotidectomy with facial nerve reconstruction, adjuvant IMRT, and HER2-directed and androgen deprivation systemic therapy of modern salivary duct carcinoma care.
Why Salivary Duct Carcinoma Tech Platforms Require Specialized Monitoring Attention
Salivary duct carcinoma management is defined by four platform-dependent complexities: the surgical pathology platform providing HER2 and AR molecular profiling that determine systemic therapy selection; the head and neck surgery platform supporting total parotidectomy with facial nerve sacrifice and nerve reconstruction; the adjuvant radiation oncology platform delivering IMRT to the primary site and regional nodes; and the medical oncology platform managing HER2-directed and androgen deprivation systemic therapy with toxicity monitoring.
Surgical pathology platforms drive HER2 and AR status that determine first-line systemic therapy. HER2 IHC 3+ or FISH-amplified (trastuzumab + pertuzumab ± docetaxel for first-line metastatic HER2-positive salivary duct carcinoma — the most evidence-supported systemic therapy approach in salivary duct carcinoma), AR-positive by IHC (androgen deprivation therapy — leuprolide plus bicalutamide or enzalutamide for AR-positive HER2-negative or dual-positive salivary duct carcinoma), and the HER2/AR dual-positive phenotype (combination HER2 plus AR targeting under investigation) are the molecular determinations that drive first-line systemic therapy selection in recurrent or metastatic salivary duct carcinoma. Monitor surgical pathology platforms during diagnostic hours.
Head and neck surgery platforms support total parotidectomy with facial nerve sacrifice and reconstruction. Salivary duct carcinoma's frequent direct facial nerve invasion, perineural invasion of facial nerve branches, and T4a disease stage (skin, mandible, ear canal, or facial nerve invasion) mean that total parotidectomy with planned facial nerve sacrifice and immediate sural nerve cable graft reconstruction is a common surgical approach — with detailed intraoperative facial nerve monitoring records, cable graft harvest records, and immediate reconstruction records critical for postoperative care planning. Monitor head and neck surgery platforms during operative and perioperative hours.
Adjuvant IMRT platforms cover the primary site and comprehensive regional nodes. Given the high rates of lymph node metastasis (50–60% at presentation), extranodal extension, perineural invasion, and high-grade histology, adjuvant IMRT covering the parotid bed plus ipsilateral and potentially bilateral regional nodal basins is standard — a comprehensive regional nodal IMRT field that requires careful OAR planning. Monitor radiation oncology platforms during treatment delivery hours.
HER2-directed and androgen deprivation therapy platforms require careful toxicity monitoring. Trastuzumab plus pertuzumab cardiotoxicity (left ventricular ejection fraction [LVEF] monitoring — baseline and every 3-month echocardiogram or MUGA scan during HER2-directed therapy), T-DXd interstitial lung disease (ILD) monitoring (high-alert toxicity requiring pulmonary surveillance and graded management), and enzalutamide CNS toxicity monitoring (fatigue, cognitive effects, rare seizures) are the toxicity management requirements that demand platform continuity during treatment. Monitor medical oncology platforms during clinical hours.
What to Monitor on a Salivary Duct Carcinoma Tech Platform
Surgical Pathology Platforms
Monitor salivary duct carcinoma surgical pathology records (high-grade ductal histology confirmation — comedonecrosis, Roman bridge formations, pleomorphic nuclei, high mitotic count per 10 HPF; T-stage — T1: ≤2 cm; T2: >2 cm, ≤4 cm; T3: >4 cm or extraparenchymal extension; T4a: skin, mandible, ear canal, facial nerve invasion; T4b: skull base, pterygoid plates, carotid encasement; margin status — millimeters from inked margin; perineural invasion — named facial nerve branch documentation; lymphovascular invasion; lymph node status — number examined, number positive, extranodal extension), HER2 IHC records (score 0/1+/2+/3+ using breast cancer criteria; IHC 2+ equivocal cases reflexed to FISH), HER2 FISH records (HER2/CEP17 ratio and average HER2 copy number for equivocal IHC cases; FISH-amplified definition: ratio ≥2.0 or average HER2 copy number ≥6.0), AR IHC records (Allred score — proportion score + intensity score; H-score; ≥1% nuclear staining threshold for AR positivity in salivary duct carcinoma), GATA3 IHC and GCDFP-15 IHC records (breast-lineage marker positivity supporting salivary duct carcinoma diagnosis), HRAS mutation NGS records (HRAS Q61 mutations — present in approximately 15–20%; potentially actionable with MEK inhibitors or tipifarnib farnesyl transferase inhibitor), TP53 mutation NGS records, PIK3CA/PTEN alteration records, and comprehensive molecular profiling records (TMB, MSI, PD-L1 TPS). Alert immediately — surgical pathology platform failures when the medical oncologist awaiting HER2 FISH results and AR IHC scoring needs to determine first-line systemic therapy for a patient with newly diagnosed recurrent metastatic salivary duct carcinoma.
Head and Neck Surgery Platforms
Monitor total parotidectomy operative records (total parotidectomy — complete lateral and deep lobe removal; facial nerve sacrifice records — planned sacrifice for direct tumor invasion or perineural invasion of the main trunk; immediate cable graft reconstruction — sural nerve harvest, number of fascicles, anastomosis technique; radical parotidectomy with skin flap and external auditory canal resection for T4a involvement), facial nerve monitoring records (continuous intraoperative NIM EMG; pre-sacrifice stimulation thresholds documenting nerve function status; postoperative House-Brackmann grade), neck dissection records (ipsilateral selective or modified radical neck dissection; lymph node basin documentation — levels I–V; extranodal extension documentation), free flap reconstruction records (anterolateral thigh free flap or other reconstruction for large T4 defects), and mandibular resection records for T4a mandible involvement. Alert immediately — head and neck surgery platform failures prevent the postoperative care team from accessing total parotidectomy operative records documenting the planned facial nerve sacrifice and cable graft reconstruction technique — records needed by the recovery room team assessing the patient's anticipated complete facial paralysis (House-Brackmann VI) and initiating immediate eye protection protocols for lagophthalmos.
Adjuvant Radiation Oncology Platforms
Monitor IMRT simulation and treatment planning records for salivary duct carcinoma (CT simulation — patient immobilization; GTV delineation — primary tumor bed, positive regional nodes, extranodal extension zones; CTV high-risk — parotid bed, involved nodal basins; CTV intermediate-risk — elective nodal coverage ipsilateral neck ± contralateral neck for bilateral nodal disease; dose prescription — 66 Gy/33 fx high-risk CTV, 60 Gy/30 fx intermediate-risk; OAR constraints — contralateral parotid mean <24 Gy; bilateral cochleae mean <20 Gy; spinal cord <45 Gy; brainstem <54 Gy; mandible D2% <70 Gy; oral cavity mean <40 Gy), daily IMRT fraction delivery records (CBCT image guidance positional verification; beam delivery MU logs; toxicity monitoring records — mucositis CTCAE grade, dermatitis, xerostomia, dysphagia, weight loss), and post-radiotherapy response assessment records. Alert immediately — adjuvant radiation oncology platform failures during salivary duct carcinoma IMRT prevent the radiation therapist from accessing prior fraction delivery records and CBCT image guidance positional verification needed before proceeding with the current fraction.
HER2-Directed and Androgen Deprivation Therapy Platforms
Monitor HER2-directed therapy records (trastuzumab + pertuzumab — loading doses and maintenance doses; trastuzumab emtansine [T-DM1] or trastuzumab deruxtecan [T-DXd] for HER2-positive disease after trastuzumab progression; baseline LVEF by echocardiogram or MUGA before trastuzumab initiation; serial LVEF monitoring at 3-month intervals during trastuzumab — interruption threshold: LVEF drop >10% or LVEF <50%; T-DXd ILD monitoring — chest CT at baseline and with any respiratory symptoms; ILD grade 1–2 management: treatment hold and corticosteroids; ILD grade 3–4: permanent discontinuation), androgen deprivation therapy records (leuprolide depot injection records; bicalutamide antiandrogen records; PSA monitoring for AR-positive disease response; enzalutamide dosing and CNS toxicity monitoring — fatigue, cognitive effects, seizure risk assessment; testosterone level monitoring for castration confirmation), and cytotoxic chemotherapy records (carboplatin/paclitaxel or cisplatin for rapidly progressive or visceral crisis disease). Alert immediately — HER2-directed therapy platform failures when a patient on trastuzumab + pertuzumab for HER2-amplified metastatic salivary duct carcinoma requires urgent access to the prior cycle LVEF echocardiogram result documenting LVEF 55% (baseline 65%) to determine whether the 10% drop requires trastuzumab interruption per cardiotoxicity monitoring guidelines.
Molecular Profiling Platforms
Monitor HER2 IHC and FISH records (HER2 3+ or FISH-amplified — trastuzumab eligibility), AR IHC records (AR H-score ≥10 — androgen deprivation therapy eligibility), comprehensive NGS records (HRAS Q61 mutations for MEK inhibitor or tipifarnib trial eligibility; PIK3CA hotspot mutations; PTEN loss; TP53; NF1; TMB; MSI; PD-L1 TPS for pembrolizumab immunotherapy eligibility), and LVEF echocardiogram records (cardiac function monitoring during HER2-directed therapy). Alert immediately — molecular profiling platform failures prevent the medical oncologist from accessing HER2 FISH amplification results and AR IHC H-score needed to determine first-line systemic therapy assignment in a newly diagnosed metastatic salivary duct carcinoma patient.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Salivary duct carcinoma programs coordinate across surgical pathology (HER2 IHC/FISH, AR IHC, NGS), head and neck surgery (total parotidectomy with facial nerve sacrifice, cable graft reconstruction, neck dissection), radiation oncology (comprehensive regional node IMRT), medical oncology (trastuzumab + pertuzumab, T-DXd, enzalutamide, leuprolide), cardiology (LVEF monitoring for HER2-directed cardiotoxicity), pulmonology (T-DXd ILD monitoring), reconstructive surgery (free flap for T4 defects), ophthalmology (lagophthalmos management after facial nerve sacrifice), and multidisciplinary tumor board.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, surgical pathology reporting systems, HER2/AR molecular profiling platforms, head and neck surgery operative platforms, radiation therapy delivery systems, medical oncology administration platforms, cardiology echocardiogram reporting systems, and multidisciplinary tumor board platforms.
HIPAA and Oncology Data Privacy Considerations
Salivary duct carcinoma technology platforms handle sensitive PHI including HER2 molecular profiling records (with direct-to-consumer oncology data privacy implications), planned facial nerve sacrifice records and postoperative House-Brackmann VI complete facial paralysis documentation (visible disability with employment and self-image consequences), androgen deprivation therapy records including testosterone levels and PSA monitoring (sensitive endocrine and oncology data), LVEF echocardiogram serial monitoring records (cardiac function data with life insurance implications), T-DXd ILD monitoring records (severe pulmonary toxicity records with employment and disability implications), and rapidly progressive metastatic disease records (aggressive prognosis information affecting employment, insurance, and care planning).
Alerting Strategy for Salivary Duct Carcinoma Tech Platforms
Immediate alerting during surgical pathology reporting: HER2 IHC, HER2 FISH, AR IHC, and NGS platforms — HER2 and AR status determine first-line systemic therapy in metastatic disease.
Immediate alerting during total parotidectomy and neck dissection: Head and neck surgery operative platforms with facial nerve sacrifice, cable graft reconstruction, and neck dissection records.
Immediate alerting during adjuvant IMRT delivery: Radiation therapy delivery platforms with daily CBCT image guidance and comprehensive regional nodal field fraction delivery verification.
Immediate alerting during HER2-directed and androgen deprivation therapy: Trastuzumab, pertuzumab, T-DXd, enzalutamide, and leuprolide administration platforms with LVEF and ILD monitoring.
Immediate alerting during cardiac and pulmonary toxicity monitoring: Echocardiogram LVEF monitoring during trastuzumab; chest CT ILD monitoring during T-DXd.
Sustained-failure alert (10–15 minutes): Facial nerve rehabilitation, ophthalmology lagophthalmos management, speech-language pathology, and multidisciplinary tumor board platforms.
30-day advance warning: SSL certificates across all domains.
Status Page for Salivary Duct Carcinoma Care Team Communication
A real-time status page gives surgical pathologists confirming HER2 FISH amplification and AR IHC H-score, head and neck surgeons accessing facial nerve sacrifice and cable graft reconstruction operative records, radiation oncologists verifying comprehensive regional node IMRT daily fraction delivery, medical oncologists reviewing LVEF echocardiogram results for trastuzumab cardiotoxicity management, and multidisciplinary tumor board members coordinating HER2 plus AR targeting strategy immediate platform visibility without requiring IT support contact.
Include the status page URL in salivary duct carcinoma pathology downtime procedures, head and neck surgery operative downtime protocols, adjuvant IMRT delivery downtime procedures, and HER2-directed and androgen deprivation therapy administration downtime protocols.
Vigilmon Setup for Salivary Duct Carcinoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Surgical pathology platform / HER2 IHC, HER2 FISH, AR IHC | 1 min | Slack + PagerDuty (diagnostic hours) | | Head and neck surgery platform / total parotidectomy, facial nerve sacrifice, cable graft | 1 min | Slack + PagerDuty (operative hours) | | Adjuvant IMRT platform / comprehensive regional nodal field delivery and CBCT | 1 min | Slack + PagerDuty (treatment hours) | | HER2-directed therapy platform / trastuzumab + pertuzumab, T-DXd | 1 min | Slack + PagerDuty (clinical hours) | | Androgen deprivation therapy platform / enzalutamide, leuprolide + bicalutamide | 1 min | Slack + PagerDuty (clinical hours) | | LVEF echocardiogram monitoring platform / trastuzumab cardiotoxicity | 1 min | Slack + PagerDuty (clinical hours) | | T-DXd ILD monitoring platform / chest CT surveillance | 1 min | Slack + PagerDuty (clinical hours) | | Molecular profiling platform / HER2 FISH, AR IHC, HRAS/PIK3CA NGS | 1 min | Slack + PagerDuty (diagnostic hours) | | CT staging and surveillance platform / pulmonary, hepatic, osseous metastasis | 1 min | Slack + PagerDuty (diagnostic hours) | | Facial nerve rehabilitation platform / House-Brackmann recovery or static reanimation | 2 min | Slack (clinical hours) | | Ophthalmology platform / lagophthalmos and corneal protection management | 2 min | Slack (clinical hours) | | Multidisciplinary head and neck tumor board | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure surgical pathology platforms with immediate alerting — HER2 IHC/FISH and AR IHC determine trastuzumab and androgen deprivation therapy eligibility
- Add head and neck surgery platforms with immediate alerting — facial nerve sacrifice, cable graft reconstruction, and neck dissection records are critical for postoperative care and rehabilitation planning
- Configure adjuvant IMRT platforms with immediate alerting for comprehensive regional nodal field delivery including daily CBCT image guidance verification
- Add HER2-directed therapy platforms — trastuzumab + pertuzumab, T-DXd — with LVEF cardiotoxicity monitoring and ILD surveillance
- Configure androgen deprivation therapy platforms — enzalutamide, leuprolide — with PSA response and CNS toxicity monitoring
- Add molecular profiling platforms — HER2 FISH, AR IHC, HRAS/PIK3CA NGS, comprehensive profiling
- Configure staging and surveillance CT platforms for rapid distant metastasis detection (pulmonary, hepatic, osseous)
- Add facial nerve rehabilitation and ophthalmology platforms for lagophthalmos management after facial nerve sacrifice
- Enable SSL certificate monitoring across all clinical, pathology, operative, RT delivery, HER2/AR therapy, cardiology, and tumor board domains
Conclusion
Salivary duct carcinoma technology platforms are embedded in clinical decisions where surgical pathology platform availability for HER2 molecular profiling and AR immunohistochemical quantification — where the surgical pathologist must score HER2 expression using breast cancer IHC criteria (0: no staining or membrane staining <10% of cells; 1+: faint/incomplete membrane staining in ≥10% of cells — negative; 2+: weak-to-moderate complete membrane staining in ≥10% of cells — equivocal, reflex to FISH; 3+: strong complete membrane staining in ≥10% of cells — positive, trastuzumab eligible without FISH), perform HER2 FISH for all IHC 2+ equivocal cases using the ASCO/CAP 2018 criteria (FISH-positive: HER2/CEP17 ratio ≥2.0 with average HER2 signals ≥4.0, or ratio <2.0 with average HER2 copy number ≥6.0), quantify AR expression by IHC H-score (proportion score × intensity score; ≥10% nuclear AR staining is the most commonly used threshold for androgen deprivation therapy eligibility in salivary duct carcinoma), and report HRAS Q61 mutation status (present in 15–20% of cases; tipifarnib [a farnesyl transferase inhibitor] has demonstrated meaningful activity in HRAS-mutant salivary gland carcinoma per the AIM-HN trial, with 50% ORR in HRAS-mutant head and neck carcinomas including salivary duct carcinoma) — before the medical oncologist can determine whether to initiate trastuzumab plus pertuzumab (HER2-positive salivary duct carcinoma — the strongest molecular target in this aggressive disease), enzalutamide or leuprolide plus bicalutamide androgen deprivation (AR-positive HER2-negative salivary duct carcinoma), combination HER2 plus AR targeting (dual-positive phenotype), or tipifarnib for HRAS-mutant disease — cannot be interrupted by platform outage when HER2 FISH amplification is the specific molecular result that gates trastuzumab eligibility, when AR H-score ≥10 is the IHC threshold that gates androgen deprivation therapy, and when HRAS Q61 mutation status is the molecular result that determines tipifarnib eligibility in a patient with rapidly progressive metastatic salivary duct carcinoma; where head and neck surgery platform availability immediately after total parotidectomy with planned facial nerve sacrifice enables the postoperative recovery team to access the intraoperative operative notes documenting the nerve sacrifice at the main trunk level, the sural nerve cable graft harvest (15 cm sural nerve graft, three fascicles; anastomosis to the five distal facial nerve branch stumps), and the immediate static procedures performed (gold weight implant for upper eyelid — 1.4g; lower eyelid tightening for lagophthalmos prevention) — records needed by the recovery room nursing team to implement the eye protection protocol (methylcellulose drops every 2 hours, moisture chamber goggles for sleep), initiate the facial nerve rehabilitation consultation, and document the planned House-Brackmann VI (complete paralysis) postoperative facial function as the expected surgical outcome documented preoperatively and consented to — not an operative complication; and where HER2-directed therapy platform availability during cycle 4 of trastuzumab plus pertuzumab for HER2-amplified metastatic salivary duct carcinoma — where the medical oncologist must access the cycle 3 LVEF echocardiogram result (LVEF 52% — down from baseline 65%, a 13% absolute decrease meeting the trastuzumab interruption threshold), the cardiology consultation note recommending trastuzumab hold for 3–6 weeks with repeat echocardiogram before rechallenge, and the prior infusion tolerance records documenting Grade 1 fever and chills managed with acetaminophen and diphenhydramine premedication at cycle 1 — cannot be interrupted by platform outage when the LVEF trend across the serial echocardiogram records is the safety monitoring chain that determines whether trastuzumab can be safely continued, when the cardiotoxicity interruption decision directly affects the patient's HER2-directed therapy duration and disease control, and when the prior infusion tolerance records are the premedication protocol basis for the cycle 4 infusion that cannot safely proceed without documented prior tolerance assessment.
Uptime monitoring gives salivary duct carcinoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to surgical pathology programs confirming HER2 amplification and AR positivity, head and neck surgery programs performing total parotidectomy with facial nerve sacrifice and cable graft reconstruction, radiation oncology programs delivering comprehensive regional node IMRT, medical oncology programs managing trastuzumab, pertuzumab, T-DXd, enzalutamide, and tipifarnib with cardiotoxicity and ILD surveillance, cardiology programs performing serial LVEF monitoring during HER2-directed therapy, molecular oncology programs determining HER2, AR, HRAS, and comprehensive NGS profiling for targeted therapy eligibility, facial nerve rehabilitation and ophthalmology programs managing the post-parotidectomy facial nerve sacrifice rehabilitation pathway, multidisciplinary head and neck tumor board programs coordinating the HER2/AR molecular-guided systemic therapy strategy, and compliance auditors that platform operational reliability matches the HER2 molecular profiling precision, AR immunohistochemical quantification accuracy, facial nerve sacrifice operative documentation, comprehensive regional nodal IMRT delivery verification, cardiotoxicity LVEF monitoring continuity, and ILD pulmonary surveillance that modern salivary duct carcinoma care demands.
Start monitoring your salivary duct carcinoma care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #salivarductcarcinoma #salivaryglandcancer #parotidcancer #HER2 #trastuzumab #pertuzumab #TDXd #androgenreceptor #enzalutamide #leuprolide #HRAS #tipifarnib #parotidectomy #facialnerve #IMRT #adjuvantradiotherapy #lagophthalmos #LVEF #cardiotoxicity #ILD #headandneckcancer #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre